Study of ENMD-2076 in Patients With Multiple Myeloma

Phase 1 Completed 13 enrolled CASI pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Safety, tolerability, maximum tolerated dose and clinical benefit of ENMD-2076 administered over a range of doses in patients with relapsed or refractory multiple myeloma.

Timeline

Start: 2008-12
Primary completion: 2011-11
Completion: 2012-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENMD-2076	Small molecule	—	Oral

Study of ENMD-2076 in Patients With Multiple Myeloma

Summary

Timeline

Drugs

Indications